Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)

Inclusion Criteria

• Participants must agree to follow the reproductive criteria as outlined in the protocol
• Participants have completed a qualifying Parent Study, were still receiving elranatamab when the Parent Study terminated or completed, and are deriving clinical benefit from elranatamab (as determined by the investigator).

Exclusion Criteria

• Any medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.
• Participants not previously enrolled or who have discontinued study treatment in a Parent Study are ineligible for participation in this study.